TY - JOUR
T1 - Natural products with potential to treat RNA virus pathogens including SARS-CoV‑2
AU - Christy, Mitchell P.
AU - Uekusa, Yoshinori
AU - Gerwick, Lena
AU - Gerwick, William H.
N1 - Funding Information:
We thank J. Matthews for creating Figures 1–3 and R. Rex, NIH R01 NS109075, and the UCSD Chancellor’s Office for generous financial assistance used in the construction of the manuscript. We further dedicate this review to R. Rex, a believer in the multidimensional value of scientific research.
Publisher Copyright:
© 2020 American Chemical Society and American Society of Pharmacognosy
PY - 2021/1/22
Y1 - 2021/1/22
N2 - Three families of RNA viruses, the Coronaviridae, Flaviviridae, and Filoviridae, collectively have great potential to cause epidemic disease in human populations. The current SARS-CoV-2 (Coronaviridae) responsible for the COVID-19 pandemic underscores the lack of effective medications currently available to treat these classes of viral pathogens. Similarly, the Flaviviridae, which includes such viruses as Dengue, West Nile, and Zika, and the Filoviridae, with the Ebola-type viruses, as examples, all lack effective therapeutics. In this review, we present fundamental information concerning the biology of these three virus families, including their genomic makeup, mode of infection of human cells, and key proteins that may offer targeted therapies. Further, we present the natural products and their derivatives that have documented activities to these viral and host proteins, offering hope for future mechanism-based antiviral therapeutics. By arranging these potential protein targets and their natural product inhibitors by target type across these three families of virus, new insights are developed, and crossover treatment strategies are suggested. Hence, natural products, as is the case for other therapeutic areas, continue to be a promising source of structurally diverse new anti-RNA virus therapeutics.
AB - Three families of RNA viruses, the Coronaviridae, Flaviviridae, and Filoviridae, collectively have great potential to cause epidemic disease in human populations. The current SARS-CoV-2 (Coronaviridae) responsible for the COVID-19 pandemic underscores the lack of effective medications currently available to treat these classes of viral pathogens. Similarly, the Flaviviridae, which includes such viruses as Dengue, West Nile, and Zika, and the Filoviridae, with the Ebola-type viruses, as examples, all lack effective therapeutics. In this review, we present fundamental information concerning the biology of these three virus families, including their genomic makeup, mode of infection of human cells, and key proteins that may offer targeted therapies. Further, we present the natural products and their derivatives that have documented activities to these viral and host proteins, offering hope for future mechanism-based antiviral therapeutics. By arranging these potential protein targets and their natural product inhibitors by target type across these three families of virus, new insights are developed, and crossover treatment strategies are suggested. Hence, natural products, as is the case for other therapeutic areas, continue to be a promising source of structurally diverse new anti-RNA virus therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85100280486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100280486&partnerID=8YFLogxK
U2 - 10.1021/acs.jnatprod.0c00968
DO - 10.1021/acs.jnatprod.0c00968
M3 - Review article
C2 - 33352046
AN - SCOPUS:85100280486
SN - 0163-3864
VL - 84
SP - 161
EP - 182
JO - Journal of Natural Products
JF - Journal of Natural Products
IS - 1
ER -